Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients-Report from the German SIOP-LGG 2004 cohort

Daniela Kandels, Torsten Pietsch, Brigitte Bison, Monika Warmuth-Metz, Ulrich-Wilhelm Thomale, Rolf-Dieter Kortmann, Beate Timmermann, Pablo Hernáiz Driever, Olaf Witt, René Schmidt, Astrid K Gnekow, Daniela Kandels, Torsten Pietsch, Brigitte Bison, Monika Warmuth-Metz, Ulrich-Wilhelm Thomale, Rolf-Dieter Kortmann, Beate Timmermann, Pablo Hernáiz Driever, Olaf Witt, René Schmidt, Astrid K Gnekow

Abstract

First-line treatment of pediatric low-grade glioma using surgery, radio- or chemotherapy fails in a relevant proportion of patients. We analyzed efficacy of subsequent surgical and nonsurgical therapies of the German cohort of the SIOP-LGG 2004 study (2004-2012, 1558 registered patients; median age at diagnosis 7.6 years, median observation time 9.2 years, overall survival 98%/96% at 5/10 years, 15% neurofibromatosis type 1 [NF1]). During follow-up, 1078/1558 patients remained observed without (n = 217), with 1 (n = 707), 2 (n = 124) or 3 to 6 (n = 30) tumor volume reductions; 480/1558 had 1 (n = 332), 2 (n = 80), 3 or more (n = 68) nonsurgical treatment-lines, accompanied by up to 4 tumor-reductive surgeries in 215/480; 265/480 patients never underwent any neurosurgical tumor volume reduction (163/265 optic pathway glioma). Patients with progressing tumors after first-line adjuvant treatment were at increased risk of suffering further progressions. Risk factors were young age (<1 year) at start of treatment, tumor dissemination or progression within 18 months after start of chemotherapy. Progression-free survival rates declined with subsequent treatment-lines, yet remaining higher for patients with NF1. In non-NF1-associated tumors, vinblastine monotherapy vs platinum-based chemotherapy was noticeably less effective when used as second-line treatment. Yet, for the entire cohort, results did not favor a certain sequence of specific treatment options. Rather, all can be aligned as a portfolio of choices which need careful balancing of risks and benefits. Future molecular data may predict long-term tumor biology.

Trial registration: ClinicalTrials.gov NCT00276640.

Keywords: chemotherapy; pediatric low-grade glioma; progression; radiotherapy; surgery.

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

References

REFERENCES

    1. Stokland T, Liu JF, Ironside JW, et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol. 2010;12:1257-1268.
    1. Gnekow AK, Falkenstein F, von Hornstein S, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14:1265-1284.
    1. Bandopadhayay P, Bergthold G, London WB, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014;61:1173-1179.
    1. Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35:2370-2377.
    1. Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:4572-4578.
    1. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:2641-2647.
    1. Ater JL, Xia C, Mazewski CM, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children's Oncology Group. Cancer. 2016;122:1928-1936.
    1. Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study. J Clin Oncol. 2016;34:3537-3543.
    1. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30:1358-1363.
    1. Massimino M, Spreafico F, Riva D, et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010;100:65-71.
    1. Mishra KK, Puri DR, Missett BT, et al. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol. 2006;8:166-174.
    1. Merchant TE, Kun LE, Wu S, Xiong X, Sanford RA, Boop FA. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2009;27:3598-3604.
    1. Cherlow JM, Shaw DWW, Margraf LR, et al. Conformal radiation therapy for pediatric patients with low-grade glioma: results from the Children's Oncology Group phase 2 study ACNS0221. Int J Radiat Oncol Biol Phys. 2019;103:861-868.
    1. Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery. 2011;68:1548-1554.
    1. Gnekow AK, Walker DA, Kandels D, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017;81:206-225.
    1. de Haas V, Grill J, Raquin MA, et al. Relapses of optic pathway tumors after first-line chemotherapy. Pediatr Blood Cancer. 2009;52:575-580.
    1. Scheinemann K, Bartels U, Tsangaris E, et al. Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas. Pediatr Blood Cancer. 2011;57:84-88.
    1. Greenberger BA, Pulsifer MB, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2014;89:1060-1068.
    1. Huynh-Le MP, Walker AJ, Burger PC, et al. Management of pediatric intracranial low-grade gliomas: long-term follow-up after radiation therapy. Childs Nerv Syst. 2016;32:1425-1430.
    1. Goebel AM, Gnekow AK, Kandels D, Witt O, Schmidt R, Hernaiz Driever P. Natural history of pediatric low-grade glioma disease - first multi-state model analysis. J Cancer. 2019;10:6314-6326.
    1. Muller K, Gnekow A, Falkenstein F, et al. Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol. 2013;189:647-655.
    1. Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol. 2009;27:3691-3697.
    1. Tsang DS, Murphy ES, Merchant TE. Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys. 2017;99:642-651.
    1. Aarsen FK, Paquier PF, Arts WF, et al. Cognitive deficits and predictors 3 years after diagnosis of a pilocytic astrocytoma in childhood. J Clin Oncol. 2009;27:3526-3532.
    1. Krishnatry R, Zhukova N, Guerreiro Stucklin AS, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122:1261-1269.
    1. Gnekow AK, Kandels D, van Tilburg C, et al. SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 2019;231:107-135.
    1. Gururangan S, Fangusaro J, Poussaint TY, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas-a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014;16:310-317.
    1. Azizi AA, Schouten-van Meeteren AYN. Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey. J Neurooncol. 2018;136:127-134.
    1. Fisher PG, Tihan T, Goldthwaite PT, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer. 2008;51:245-250.
    1. D'Arco F, Culleton S, De Cocker LJL, Mankad K, Davila J, Tamrazi B. Current concepts in radiologic assessment of pediatric brain tumors during treatment, part 1. Pediatr Radiol. 2018;48:1833-1843.
    1. Tamrazi B, Mankad K, Nelson M, D'Arco F. Current concepts and challenges in the radiologic assessment of brain tumors in children: part 2. Pediatr Radiol. 2018;48:1844-1860.
    1. Warren KE, Poussaint TY, Vezina G, et al. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013;60:1397-1401.
    1. Falkenstein F, Gessi M, Kandels D, et al. Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II - report from the German/Swiss SIOP-LGG 2004 cohort. Int J Cancer. 2020.
    1. Garzon M, Garcia-Fructuoso G, Sunol M, Mora J, Cruz O. Low-grade gliomas in children: single institutional experience in 198 cases. Childs Nerv Syst. 2015;31:1447-1459.
    1. Roder C, Breitkopf M, Bisdas S, et al. Beneficial impact of high-field intraoperative magnetic resonance imaging on the efficacy of pediatric low-grade glioma surgery. Neurosurg Focus. 2016;40:E13.
    1. Holzapfel J, Kandels D, Schmidt R, et al. Favorable prognosis in pediatric brainstem low-grade glioma: report from the German SIOP-LGG 2004 cohort. Int J Cancer. 2020;146:3385-3396.
    1. Matyja E, Grajkowska W, Stępień K, Naganska E. Heterogeneity of histopathological presentation of pilocytic astrocytoma - diagnostic pitfalls. A review. Folia Neuropathol. 2016;54:197-211.
    1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC Press; 2016.
    1. von Hornstein S, Kortmann RD, Pietsch T, et al. Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial. Pediatr Blood Cancer. 2011;56:1046-1054.
    1. Indelicato DJ, Rotondo RL, Uezono H, et al. Outcomes following proton therapy for pediatric low-grade glioma. Int J Radiat Oncol Biol Phys. 2019;104:149-156.
    1. Mirow C, Pietsch T, Berkefeld S, et al. Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatr Blood Cancer. 2014;61:457-463.
    1. Dodgshun AJ, Hansford JR, Sullivan MJ. Risk assessment in paediatric glioma-time to move on from the binary classification. Crit Rev Oncol Hematol. 2017;111:52-59.
    1. Balogun JA, Rutka JT. Surgery of intracranial gliomas in children. Prog Neurol Surg. 2018;30:204-217.
    1. Tsang DS, Murphy ES, Lucas JT Jr, Lagiou P, Acharya S, Merchant TE. Pseudoprogression in pediatric low-grade glioma after irradiation. J Neurooncol. 2017;135:371-379.
    1. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9:161-168.
    1. Bitterman DS, MacDonald SM, Yock TI, et al. Revisiting the role of radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2019;37:3335-3339.
    1. Acharya S, Liu JF, Tatevossian RG, et al. Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. Neuro Oncol. 2020.
    1. de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31:21-27.
    1. Fouladi M, Hunt DL, Pollack IF, et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945. Cancer. 2003;98:1243-1252.
    1. Yang RR, Aibaidula A, Wang WW, et al. Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathol. 2018;136:641-655.
    1. Ho CY, Mobley BC, Gordish-Dressman H, et al. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol. 2015;130:575-585.
    1. Bergthold G, Bandopadhayay P, Hoshida Y, et al. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015;17:1486-1496.
    1. Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8:30.
    1. Frazao L, do Carmo Martins M, Nunes VM, et al. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - markers in the clinical stratification of pediatric gliomas. BMC Cancer. 2018;18:1259.
    1. Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018;33:73-81.
    1. Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14:790-797.
    1. D'Angelo F, Ceccarelli M, Tala, et al. The molecular landscape of glioma in patients with neurofibromatosis 1. Nat Med. 2019;25:176-187.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다